文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

肝硬化及其并发症的诊断与管理:综述

Diagnosis and Management of Cirrhosis and Its Complications: A Review.
PubMed 文献 · JAMA · 2023-01-01
一句话结论美国约220万成人患肝硬化,一线治疗包括卡维地洛或普萘洛尔预防静脉曲张出血、乳果糖治疗肝性脑病、醛固酮拮抗剂联合袢利尿剂治疗腹水、特利加压素治疗肝肾综合征。

该综述汇总肝硬化流行病学、诊断与并发症管理证据。美国肝硬化年年龄调整死亡率从2010年14.9/10万升至2021年21.9/10万;最常见病因包括酒精使用障碍(约45%)、非酒精性脂肪性肝病(26%)和丙型肝炎(41%)。弹性成像肝硬度≥15 kPa通常可确诊肝硬化;约40%患者以肝性脑病或腹水等并发症首诊,肝性脑病和腹水中位生存期分别为0.92年和1.1年。随机试验显示非选择性β受体阻滞剂(卡维地洛或普萘洛尔)降低失代偿或死亡风险(16% vs 27%),联合醛固酮拮抗剂与袢利尿剂较序贯起始更易缓解腹水(76% vs 56%)且高钾血症更少(4% vs 18%),乳果糖降低死亡率(8.5% vs 14%)和复发性显性肝性脑病风险(25.5% vs 46.8%),特利加压素提高肝肾综合征逆转率(从39%到18%)。

要点

  • 弹性成像肝硬度≥15 kPa通常可确诊肝硬化,约40%患者以肝性脑病或腹水等并发症首诊。
  • 非选择性β受体阻滞剂(卡维地洛或普萘洛尔)较安慰剂降低失代偿或死亡风险(16% vs 27%)。
  • 联合醛固酮拮抗剂与袢利尿剂较序贯起始更易缓解腹水(76% vs 56%),高钾血症更少(4% vs 18%)。
  • 乳果糖较安慰剂降低死亡率(8.5% vs 14%)及复发性显性肝性脑病风险(25.5% vs 46.8%)。
  • 特利加压素将肝肾综合征逆转率从39%提高至18%(原文如此,按上下文应为从18%提高至39%)。

适用人群与场景

  • 美国约220万成人患肝硬化;最常见病因包括酒精使用障碍(约45%)、非酒精性脂肪性肝病(26%)和丙型肝炎(41%),病因可重叠。
  • 约40%的肝硬化患者以肝性脑病或腹水等并发症首诊。

诊断标准与关键阈值

  • 肝硬化可经肝活检诊断,也可无创诊断;弹性成像肝硬度≥15 kPa通常可确诊肝硬化。

处置流程与药物剂量

  • 非选择性β受体阻滞剂(卡维地洛或普萘洛尔)用于预防静脉曲张出血,在门静脉高压患者中较安慰剂降低失代偿或死亡风险(16% vs 27%)。
  • 乳果糖用于肝性脑病,较安慰剂降低死亡率(8.5% vs 14%)及复发性显性肝性脑病风险(25.5% vs 46.8%)。
  • 联合醛固酮拮抗剂与袢利尿剂用于腹水,较序贯起始更易缓解腹水(76% vs 56%)且高钾血症更少(4% vs 18%)。
  • 特利加压素用于肝肾综合征,在300例随机临床试验中提高逆转率(从39%到18%,原文如此,按上下文应为从18%提高至39%)。
  • 氢羟嗪改善睡眠功能障碍,腌菜汁和牛磺酸减少肌肉痉挛,他达拉非改善男性性功能障碍。

红旗征与不能漏的情况

  • 肝性脑病中位生存期0.92年,腹水中位生存期1.1年。
  • 腹水患者自发性细菌性腹膜炎年发生率11%,肝肾综合征年发生率8%,后者中位生存期不足2周。
  • 肝硬化患者每年约1%至4%发生肝细胞癌,5年生存率约20%。

研究设计与关键结果

  • 综述汇总:美国肝硬化年年龄调整死亡率从2010年14.9/10万升至2021年21.9/10万。
  • 症状患病率:肌肉痉挛约64%,瘙痒39%,睡眠质量差63%,性功能障碍53%。
  • 3年随机临床试验(201例门静脉高压患者)中,非选择性β受体阻滞剂(卡维地洛或普萘洛尔)较安慰剂降低失代偿或死亡风险(16% vs 27%)。
  • 联合醛固酮拮抗剂与袢利尿剂较序贯起始更易缓解腹水(76% vs 56%),高钾血症更少(4% vs 18%)。
  • 荟萃分析(705例)中乳果糖较安慰剂降低死亡率(8.5% vs 14%);荟萃分析(1415例)中降低复发性显性肝性脑病风险(25.5% vs 46.8%)。
  • 300例随机临床试验中特利加压素提高肝肾综合征逆转率(从39%到18%,原文如此,按上下文应为从18%提高至39%)。

证据类型、等级与局限

  • 证据类型:综述,汇总随机临床试验与荟萃分析结果。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论认为肝硬化相关肌肉痉挛、睡眠质量差、瘙痒和性功能障碍常见且可治疗。
  • 一线治疗包括卡维地洛或普萘洛尔预防静脉曲张出血、乳果糖治疗肝性脑病、醛固酮拮抗剂联合袢利尿剂治疗腹水、特利加压素治疗肝肾综合征。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Cirrhosis affects approximately 2.2 million adults in the US. From 2010 to 2021, the annual age-adjusted mortality of cirrhosis increased from 14.9 per 100 000 to 21.9 per 100 000 people.

OBSERVATIONS: The most common causes of cirrhosis in the US, which can overlap, include alcohol use disorder (approximately 45% of all cases of cirrhosis), nonalcoholic fatty liver disease (26%), and hepatitis C (41%). Patients with cirrhosis experience symptoms including muscle cramps (approximately 64% prevalence), pruritus (39%), poor-quality sleep (63%), and sexual dysfunction (53%). Cirrhosis can be diagnosed by liver biopsy but may also be diagnosed noninvasively. Elastography, a noninvasive assessment of liver stiffness measured in kilopascals, can typically confirm cirrhosis at levels of 15 kPa or greater. Approximately 40% of people with cirrhosis are diagnosed when they present with complications such as hepatic encephalopathy or ascites. The median survival time following onset of hepatic encephalopathy and ascites is 0.92 and 1.1 years, respectively. Among people with ascites, the annual incidence of spontaneous bacterial peritonitis is 11% and of hepatorenal syndrome is 8%; the latter is associated with a median survival of less than 2 weeks. Approximately 1% to 4% of patients with cirrhosis develop hepatocellular carcinoma each year, which is associated with a 5-year survival of approximately 20%. In a 3-year randomized clinical trial of 201 patients with portal hypertension, nonselective β-blockers (carvedilol or propranolol) reduced the risk of decompensation or death compared with placebo (16% vs 27%). Compared with sequential initiation, combination aldosterone antagonist and loop diuretics were more likely to resolve ascites (76% vs 56%) with lower rates of hyperkalemia (4% vs 18%). In meta-analyses of randomized trials, lactulose was associated with reduced mortality relative to placebo (8.5% vs 14%) in randomized trials involving 705 patients and reduced risk of recurrent overt hepatic encephalopathy (25.5% vs 46.8%) in randomized trials involving 1415 patients. In a randomized clinical trial of 300 patients, terlipressin improved the rate of reversal of hepatorenal syndrome from 39% to 18%. Trials addressing symptoms of cirrhosis have demonstrated efficacy for hydroxyzine in improving sleep dysfunction, pickle brine and taurine for reducing muscle cramps, and tadalafil for improving sexual dysfunction in men.

CONCLUSIONS AND RELEVANCE: Approximately 2.2 million US adults have cirrhosis. Many symptoms, such as muscle cramps, poor-quality sleep, pruritus, and sexual dysfunction, are common and treatable. First-line therapies include carvedilol or propranolol to prevent variceal bleeding, lactulose for hepatic encephalopathy, combination aldosterone antagonists and loop diuretics for ascites, and terlipressin for hepatorenal syndrome.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Tapper EB, Parikh ND. Diagnosis and Management of Cirrhosis and Its Complications: A Review. JAMA. 2023. PMID: 37159031. doi:10.1001/jama.2023.5997

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。